Pomalidomide is an orally bioavailable derivative of thalidomide with potential immunomodulating, antiangiogenic and antineoplastic activities.

EVP4593 shows potent inhibitory activity toward both NF-κB activation and TNF-α production with IC50 of 11 nM and 7 nM in Jurkat T cells, respectively.

Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist.

Sepantronium Bromide is a small-molecule proapoptotic agent with potential antineoplastic activity.

AT406 is a potent Smac mimetic and an antagonist of IAP.

BV-6 is a SMAC mimetic, dual cIAP and XIAP inhibitor.

GSK2606414 is an orally available, potent, and selective PERK inhibitor.

GSK2656157 is an ATP-competitive and highly selective inhibitor of PERK.